205 related articles for article (PubMed ID: 27525431)
61. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
62. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
63. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
64. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
65. PRL secreting adenomas in male patients.
Ciccarelli A; Guerra E; De Rosa M; Milone F; Zarrilli S; Lombardi G; Colao A
Pituitary; 2005; 8(1):39-42. PubMed ID: 16411067
[TBL] [Abstract][Full Text] [Related]
66. Drug treatment of hyperprolactinemia.
Chanson P; Borson-Chazot F; Chabre O; Estour B
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
[TBL] [Abstract][Full Text] [Related]
67. Clinical management of prolactinomas.
Webster J
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):395-408. PubMed ID: 10909431
[TBL] [Abstract][Full Text] [Related]
68. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
69. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
70. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
71. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
[TBL] [Abstract][Full Text] [Related]
72. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
73. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
[TBL] [Abstract][Full Text] [Related]
74. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
75. [Prolactinoma in the male. Physiopathological, clinical, and therapeutic features].
Coppola A; Cuomo MA
Minerva Endocrinol; 1998 Mar; 23(1):7-16. PubMed ID: 9691632
[TBL] [Abstract][Full Text] [Related]
76. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Inancli SS; Usluogullari A; Ustu Y; Caner S; Tam AA; Ersoy R; Cakir B
Endocrine; 2013 Aug; 44(1):193-9. PubMed ID: 23233277
[TBL] [Abstract][Full Text] [Related]
77. [Prolactinoma treatment status in the cabergoline era].
Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
[TBL] [Abstract][Full Text] [Related]
78. Prolactinoma surgery.
Jan M; Dufour H; Brue T; Jaquet P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
[TBL] [Abstract][Full Text] [Related]
79. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
80. Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses.
Baba MS; Islam Mir SU; Bhat MH; Laway BA; Misgar RA
Cureus; 2023 Aug; 15(8):e42911. PubMed ID: 37664314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
